参考文献/References:
[1] Patel S, Srivastava S, Singh M R, et al. Mechanistic insight into diabetic wounds: pathogenesis, molecular targets and treatment strategies to pace wound healing[J]. Biomed Pharmacother, 2019, 112:108615.
[2] Ylmaz M, Kayaniek H. A new inflammatory marker: elevated monocyte to HDL cholesterol ratio associated with smoking[J]. J Clin Med, 2018, 7(4):76.
[3] Groh L, Keating S T, Joosten L, et al. Monocyte and macrophage immunometabolism in atherosclerosis[J]. Semin Immunopathol, 2018, 40(2):203-214.
[4] Chen J W, Li C, Liu Z H, et al. The role of monocyte to high-density lipoprotein cholesterol ratio in prediction of carotid intima-media thickness in patients with type 2 diabetes[J]. Front Endocrinol (Lausanne), 2019, 10:191.
[5] Ganjali S, Gotto A J, Ruscica M, et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases[J]. J Cell Physiol, 2018, 233(12):9237-9246.
[6] Lipsky B A, Aragón-Sánchez J, Diggle M, et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes[J]. Diabetes Metab Res Rev, 2016, 32 (Suppl 1):45-74.
[7] Armstrong D G, Boulton A J M, Bus S A. Diabetic foot ulcers and their recurrence[J]. N Engl J Med, 2017, 376(24):2367-2375.
[8] 李骄阳, 王亚荻, 刘丽, 等. 单核细胞/高密度脂蛋白胆固醇比值与糖尿病足溃疡感染、病情严重程度及预后的关系[J]. 中华内分泌代谢杂志, 2020, 36(6):474-478.
[9] Ganjali S, Gotto A M Jr, Ruscica M, et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases[J]. J Cell Physiol, 2018, 233(12):9237-9246.
[10] Kanbay M, Solak Y, Unal H U, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease[J]. Int Urol Nephrol, 2014, 46(8):1619-1625.
[11] Bolayir A, Gokce S F, Cigdem B, et al. Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients[J]. Neurol Neurochir Pol, 2018, 52(2):150-155.
[12] Karatas A, Turkmen E, Erdem E D et al. Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy[J]. Biomark Med, 2018, 12(9):953-959.
[13] Kolseth I B, Reine T M, Parker K, et al. Increased levels of inflammatory mediators and proinflammatory monocytes in patients with type I diabetes mellitus and nephropathy[J]. J Diabetes Complications, 2017, 31(1):245-252.